with poststent and follow-up OCT were identified from the OCT registry database of our institute. Exclusion criteria included the following (1) the DES was implanted for left main coronary disease, (2) there were overlapping DESs implanted in the lesion, (3) the clinical follow-up period after DES implantation was <1 year, (4) follow-up OCT was performed >1 year after DES implantation, and (5) the OCT image had poor quality.
C oronary stent malapposition is the separation of ≥1 stent strut from the intimal surface of the coronary arterial wall without involvement of side branches. 1 In the era of drug-eluting stents (DESs), late-acquired stent malapposition is a wellrecognized problem in interventional cardiology because it may constitute a potent substrate for late stent thrombosis. [1] [2] [3] The incidence of late-acquired stent malapposition was reported to be as high as 25% in patients with acute myocardial infarction. 4 In addition, predictors of late-acquired stent malapposition include plaque or thrombus absorption or positive vascular remodeling. 1, 5, 6 Intravascular ultrasound (IVUS) imaging was used to detect stent malapposition in previous studies. IVUS may not completely detect stent malapposition because of limited axial resolution (100-200 μm) or stent-related artifacts. 5 However, optical coherence tomography (OCT) with a higher resolution (12-18 μm) may detect stent malapposition with greater accuracy. There are limited data on detection of acute and late stent malapposition by OCT in small sample sizes. Therefore, we investigated the incidences, predictors, and clinical outcomes of acute and late stent malapposition detected by OCT in a large number of patients who received DESs.
Ultimately, 351 patients with 356 lesions were enrolled in this study. During the same study period, there were 3235 patients (3587 lesions) who underwent drug-eluting stents implantation because of stenosis of de novo lesions and 52 patients (55 lesions) with postintervention OCT alone, excluding 351 study patients. DESs were selected by operators at the time of implantation and included sirolimus-eluting stents (Cypher, Cordis, Miami, FL), zotarolimus-eluting stents (Resolute or Integrity, Medtronic, Santa Rosa, CA), everolimus-eluting stents (Xience V, Abbott Vascular, Santa Clara, CA), or biolimus A9-eluting stents (Nobori, Terumo Corporation, Tokyo, Japan or Biomatrix, Biosensors International, Singapore). Each DES was implanted using conventional techniques. Unfractionated heparin was administered as an initial bolus of 100 IU/kg with additional boluses administered during the procedure to achieve an activated clotting time of 250 to 300 seconds. Dual antiplatelet therapy (aspirin and clopidogrel) was provided to each patient until the follow-up OCT was performed. The institutional review board of Yonsei University Severance Hospital approved this study, and written informed consent was obtained from each patient.
OCT Imaging and Analyses
OCT was performed using 2 OCT systems (Model M2 Imaging System and C7-XR Imaging System, LightLab Imaging, Inc, St Jude Medical, St. Paul, MN). 7, 8 All OCT images were analyzed at a core laboratory (Cardiovascular Research Center, Seoul, Korea) by analysts who were blinded to patient and procedural information. Crosssectional OCT images were analyzed at 1-mm intervals. Stent and luminal cross-sectional areas were measured. The malapposition and neointimal hyperplasia (NIH) cross-sectional area was calculated as appropriate. 9 Once a complete set of cross-sectional area measurements was obtained, intrastent volumes (stent, lumen, malapposition, and NIH volumes) were calculated by Simpson rule. 10 NIH volume obstruction (%) was calculated as the NIH volume divided by stent volume. Mean values are reported. NIH thickness, the distance between the endoluminal surface of the neointima and the strut, was measured inside each strut with a line perpendicular to the neointima and strut. 11 The percentage of malapposed struts in each stented lesion was calculated as the (number of malapposed struts/total number of struts in all cross-sections of the lesion)×100.
A malapposed strut was defined as a strut that was detached from the vessel wall as follows: Cypher, ≥160 μm; Resolute or Integrity, ≥110 μm; Xience V, ≥100 μm; Nobori or Biomatrix, ≥130 μm. [12] [13] [14] A coronary stent malapposition that is detected immediately after implantation of the stent is classified as an acute stent malapposition, whereas one that is detected later (during a follow-up examination) is classified as a late stent malapposition. Late stent malappositions can be further classified as a late-persistent stent malappositions or lateacquired stent malappositions. A late-persistent stent malapposition is an acute stent malapposition that remains present at the follow-up examination. A late-acquired stent malapposition is a newly developed stent malapposition that is identified at the follow-up examination despite complete stent apposition during the initial procedure. If malapposed struts were detected by poststent OCT (ie, acute stent malapposition), each cross-section of the poststent OCT image was matched with corresponding cross-sectional images of the follow-up OCT image as accurately as possible based on the distance from fiduciary landmarks (eg, stent edges, side branches, or calcification). 8 The lesions were then appropriately classified as resolved acute stent malapposition lesions with or without late-acquired stent malapposition or late-persistent stent malapposition lesions with or without late-acquired stent malapposition ( Figure 1 ). In addition, the longitudinal locations of malappositions were classified as stent edges (<5 mm from the proximal or distal edge of the stent) or stent body. If malapposed struts were detected within a stent edge and stent body simultaneously, the location with the larger malapposition volume was designated as the longitudinal location of malapposition.
Angiographic Analyses
Quantitative coronary angiography analyses were performed before and after stent implantation and at the follow-up using an off-line quantitative coronary angiographic system (CASS system, Pie Medical Instruments, Maastricht, The Netherlands) in an independent core laboratory (Cardiovascular Research Center, Seoul, Korea). Reference vessel diameters and minimal luminal diameters were measured with a guiding catheter for magnification-calibration from diastolic frames in a single, matched view that showed the smallest minimal luminal diameter.
Clinical Follow-Up
All patients were advised to receive dual (aspirin and clopidogrel) antiplatelet therapy for ≥6 months after DES implantation. During the follow-up period, clinical events were investigated, including cardiovascular death, nonfatal myocardial infarction, stent thrombosis, and target lesion revascularization. Patients who experienced clinical events within the first year after DES implantation were included in this study.
Statistical Analyses
Categorical variables are presented as numbers (%). Continuous variables are presented as the mean±SD. Categorical variables were compared using χ 2 tests or Fisher exact tests. Continuous variables were compared using Student t tests, paired t tests, or 1-way ANOVA, as appropriate. If distributions were skewed, nonparametric tests were performed. Multivariate logistic regression analyses were performed to identify independent predictors of acute, late-persistent, and lateacquired stent malapposition. Variables with P values <0.2 from univariate analyses were included in multivariate analyses. Receiveroperating curve analyses were performed to identify the best cut-off value that separated late-persistent stent malapposition lesions from resolved acute stent malapposition lesions. The incidences of clinical events were presented as the proportions and compared using Fisher exact test because of the small number of clinical events. Statistical analyses were performed using the software program SPSS (version 20.0, Chicago, IL), and P<0.05 was considered statistically significant.
Results
Baseline clinical and procedural characteristics are summarized in Table 1 . There were no statistically significant differences in baseline clinical and procedural characteristics among the 351 study patients, 52 patients with post-DES OCT alone, and the remaining 3235 patients with DES implantation during the same study period (Table 1 ). Figure 2 shows the incidences of acute, late-persistent, and late-acquired stent
WHAT IS KNOWN
• There are 3 types of stent malapposition: acute, late-persistent, and late-acquired stent malapposition.
• Late-acquired stent malapposition may constitute a potent substrate for late stent thrombosis after drug-eluting stent implantation.
• There are limited data on optical coherence tomography-detected acute and late stent malapposition in small sample sizes.
WHAT THE STUDY ADDS
• Acute, late-persistent, and late-acquired stent malapposition detected by optical coherence tomography had relatively high incidences but different predictors.
• The clinical outcome of optical coherence tomography-based stent malapposition was favorable. malapposition detected by OCT at poststent and follow-up examinations. Follow-up OCT was performed on average 175±60 days after DES implantation. Acute stent malapposition was observed in 221 of 356 (62%) lesions on poststent OCT images. Among the 221 acute stent malapposition lesions, 68 (31%) were classified as late-persistent stent malapposition lesions. The remaining 153 (69%) were classified as resolved acute stent malapposition lesions based on follow-up OCT images. Late-acquired stent malapposition was identified in 23 of 68 late-persistent stent malapposition lesions and 10 of 153 resolved acute stent malapposition lesions according to follow-up OCT examinations. Follow-up OCT images showed late-acquired stent malapposition in 21 of 135 (16%) lesions lacking acute stent malapposition. Consequently, late-acquired stent malapposition was detected in 54 of 356 (15%) lesions on follow-up OCT images; sirolimuseluting stent, 16% (13/83); zotarolimus-eluting stent, 15% (18/120); everolimus-eluting stent, 13% (4/30); and biolimuseluting stent, 15% (19/123) (P=0.991).
Predictors of Acute Stent Malapposition
Poststent OCT images indicated that the percentage of acute malapposed struts was 5.2±6.2%, and the volume of acute stent malapposition was 3.05±3.67 mm 3 . Approximately half (53%) of the acute stent malappositions were located within the edges of the stents. Severe baseline diameter stenosis (>70%), calcification of the lesion, and long stent length (>25 mm) were identified as independent predictors of acute stent malapposition ( Table 2 ).
Predictors of Late-Persistent Stent Malapposition
Follow-up OCT examinations indicated that the percentage of late-persistent malapposed struts was 2.5±3.6%, and the volume of late-persistent stent malapposition was 1.28±2.16 mm 3 . Most (72%) late-persistent stent malappositions were located within the edges of the stents. In multivariate logistic regression analyses, the volume of acute stent malapposition (odds ratio, 1.17; 95% confidence interval, 1.01-1.35; P=0.044) and location of acute stent malapposition within the stent edges (odds ratio, 6.31; 95% confidence interval, 2.03-19.60; P=0.001) were identified as independent predictors of late-persistent stent malapposition. Receiver-operating curve analyses indicated that a volume of acute stent malapposition >2.56 mm 3 separated late-persistent stent malapposition lesions from resolved acute stent malapposition lesions (area under curve, 0.739; 95% confidence interval, 0.658-0.819; sensitivity, 62%; specificity, 75%; Figure 3A ). The percentage of late-persistent stent malapposition lesions according to the quintiles of total acute stent malapposition area is shown in Figure 3B ( Table 3 ).
Predictors of Late-Acquired Stent Malapposition
Follow-up OCT examinations indicated that the percentage of late-acquired malapposed struts was 3.8±4.5%, and the volume of late-acquired stent malapposition was 2.06±3.24 mm 3 . Lateacquired stent malappositions were predominantly distributed within stent bodies (61%) rather than stent edges (39%). Plaque/thrombus prolapse was observed more frequently by poststent OCT examinations in patients with late-acquired stent malapposition lesions compared with those who did not have late-acquired stent malapposition lesions ( Table 4 ).
The 356 lesions were reclassified into 4 groups according to the presence or absence of late-persistent stent malapposition and late-acquired stent malapposition on follow-up OCT examinations. The 4 groups were late-persistent stent malapposition with late-acquired stent malapposition, late-persistent stent malapposition alone, late-acquired stent malapposition alone, and no-malapposition lesions. Lesions classified as late-persistent stent malapposition with late-acquired stent malapposition had the smallest NIH thicknesses and lowest percentages of NIH volume obstruction (Figure in the Data Supplement). The mean follow-up duration for the 351 patients was 28.6±10.3 months. Clinical events that were possibly related to stent malapposition, including cardiovascular death, nonfatal myocardial infarction, and stent thrombosis, were not observed in patients with late stent malapposition ( Table 5 ). Target lesion revascularization was performed in 8 of 351 patients during the follow-up (Table 5 ). Clinical events, including cardiovascular death, nonfatal myocardial infarction, and stent thrombosis, also did not occur in 52 patients with postintervention OCT alone within the first year after DES implantation.
Discussion
To the best of our knowledge, this is the first study to investigate OCT-detected acute and late stent malapposition in a large number of patients in clinical practice. The incidence of stent malapposition detected by OCT was relatively high. Severe stenosis, calcified lesions, and longer stent length were predictors for acute stent malapposition. Predictors of late-persistent stent malapposition were the presence of acute stent malapposition within the stent edge and a larger volume of acute stent malapposition. Late-acquired stent malapposition was associated with plaque/thrombus prolapse detected on poststent OCT images. Long-term clinical outcomes of late stent malapposition detected by OCT were favorable.
Acute Stent Malapposition
Previous IVUS studies reported that the incidence of acute stent malapposition after DES implantation was 7.2% in daily clinical practice 15 and 34.3% in patients with acute myocardial infarction. 6 A recent OCT study reported that acute stent malapposition was observed in 36 of 43 (83.7%) patients who received bare-metal stents or DES. 8 In the present study, the incidence of acute stent malapposition was as high as 62%.
The higher incidence of acute stent malapposition in our study may be explained by the ability of OCT to detect small lesions with greater accuracy than IVUS. A previous study comparing poststent OCT with IVUS showed that minimal acute stent malapposition was detected by OCT in 62% of patients but was not detected by IVUS. 16 Lesion characteristics, such as calcification and severe diameter stenosis, were identified as predictors of acute stent malapposition. Heavily calcified lesions are known to preclude stent apposition, despite highpressure balloon dilation or rotational atherectomy. 17 Severe diameter stenosis and subsequent differences between the luminal diameter of the most stenotic segment and that of the reference vessel also increase the frequency of acute stent malapposition.
Late-Persistent Stent Malapposition
A significant portion (31%) of lesions with acute stent malapposition remained malapposed on follow-up OCT examinations. These results are similar with those of a previous OCT study that reported that the incidence of late-persistent stent malapposition was 28.5% for 78 segments with acute stent malapposition. 8 The present study showed improvements in stent malapposition. The percentage of malapposed struts in acute stent malapposition improved from 6.6±5.8% to 2.5±3.6% in late-persistent stent malapposition (P<0.001).
The volume of stent malapposition improved from 4.64±4.48 mm 3 in acute stent malapposition to 1.28±2.16 mm 3 in latepersistent stent malapposition (P<0.001). Improvements in stent malapposition were primarily because of NIH after DES implantation. Neointimal healing reduces the volume of acute stent malapposition with many acute stent malapposition struts becoming completely integrated into the vessel wall. However, cases of acute stent malapposition with a large volume or acute stent malapposition located within the edges of the stent were not resolved in most cases. Thus, acute stent malapposition volume and location within stent edges were identified as independent predictors of late-persistent stent malapposition.
Our results indicate that an acute stent malapposition with a larger volume or area is more likely to persist at follow-up examinations, which is consistent with findings from previous studies. 4, 6, 8 Late-persistent stent malapposition could be differentiated from resolved acute stent malapposition by an acute stent malapposition area >1.2 mm 2 according to an IVUS study. 6 A strut-to-vessel distance ≤260 µm on poststent OCT images was suggested as a cut-off value for resolved acute stent malapposition. 18 A volume of acute stent malapposition >2.56 mm 3 best separated late-persistent stent malapposition lesions from resolved acute stent malapposition lesions in the present study.
Late-Acquired Stent Malapposition
The presence of a plaque/thrombus protrusion, which was most often (75%) located within the stent body on poststent IVUS images, was reported to be a predictor of late-acquired stent malapposition. 6 Thus, it was suggested that plaque/ thrombus dissolution plays an important role in the pathogenesis of late-acquired stent malapposition. 6 The results of the IVUS study are consistent with our findings. 6 During implantation of DES, operators try to cover most of the stenotic segments that have greater burdens of plaques or thrombi. Therefore, a greater plaque/thrombus burden is usually located within the stent body rather than within the edges of the stent. A greater plaque/thrombus burden is associated with a greater risk of plaque/thrombus prolapse after stent implantation. 19, 20 Thus, it is logical that greater plaque/thrombus prolapse and late-acquired stent malapposition (because of plaque/thrombus dissolution) are usually located within the stent body.
Clinical Outcomes
The clinical implications of stent malapposition are controversial. Some studies have reported that stent malapposition is associated with adverse clinical events, whereas others have not. 2, 15, 21, 22 The incidences of clinical events are low and similar among patients with and without stent malapposition detected by OCT in the present study. Favorable clinical outcomes in the present study may be explained as follows. First, most patients (75%) received dual antiplatelet therapy for ≥12 months according to the updated guideline. 23 Second, neointimal healing continued and malapposition was reduced during the follow-up period. In addition, dual antiplatelet therapy may have prevented some ischemic events until more favorable neointimal healing was achieved. Continuous improvements in strut coverage and malapposition were confirmed previously by serial follow-up OCT examinations. 24 Third, whereas late stent thrombosis has been associated with stent malapposition of a larger-sized stent malapposition, 21 smaller-sized stent malappositions that were frequently detected by OCT may not have clinically significant impact on future major adverse cardiac events. Finally, the proportion of lesions that were implanted with new-generation DES was high (77%) in this study. Favorable clinical outcome, despite the presence of stent malapposition, may be because of the improved performance of new-generation DES. 25, 26 
Study Limitations
The present study may have potential selection bias because of the characteristics of cross-sectional investigation and exclusion of the overlapping DES-treated lesions. Preintervention OCT was not performed. Finally, the number of clinical events was too small to compare the clinical prognosis.
Conclusions
OCT-detected stent malapposition was observed frequently and had specific predictors. Long-term clinical outcomes were favorable in stent malapposition detected by OCT.
